235. Hypoparathyroidism Clinical trials / Disease details
Clinical trials : 88 / Drugs : 107 - (DrugBank : 24) / Drug target genes : 5 - Drug target pathways : 7
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03425747 (ClinicalTrials.gov) | October 15, 2019 | 27/1/2018 | Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic Hypoparathyroidism | CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM | Chronic Hypoparathyroidism | Drug: Calcium Carbonate;Drug: Calcium Citrate | Campus Bio-Medico University | NULL | Completed | 18 Years | 75 Years | All | 26 | Phase 4 | Italy |
| 2 | ChiCTR1900022194 | 2019-04-02 | 2019-03-30 | A prospective randomized controlled trial of different calcium supplementation regimens on the recovery of parathyroid function after thyroid surgery | A prospective randomized controlled trial of different calcium supplementation regimens on the recovery of parathyroid function after thyroid surgery | Hypoparathyroidism | Prophylactic group:Prophylactic calcium and vitamin D supplementation;treatment group:calcium and vitamin Dsupplementation is appropriate for hypocalcemia symptomatic patients; | West China Hospital, Sichuan University | NULL | Recruiting | 18 | 75 | Both | Prophylactic group:150;treatment group:150; | N/A | China |
| 3 | NCT04146259 (ClinicalTrials.gov) | January 1, 2017 | 29/10/2019 | Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism | Changes in Circulating Sclerostin Levels During Acute Postsurgical Hypoparathyroidism | Hypoparathyroidism Postprocedural | Drug: calcium carbonate and alphacalcidol | University of Athens | NULL | Completed | 19 Years | N/A | Female | 109 | Greece | |
| 4 | NCT01815021 (ClinicalTrials.gov) | April 2013 | 7/3/2013 | A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients | A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism. | Hypoparathyroidism | Dietary Supplement: amorphous calcium carbonate;Dietary Supplement: crystalline calcium supplements | Amorphical Ltd. | NULL | Completed | 18 Years | 80 Years | Both | 10 | Phase 1/Phase 2 | Israel |
| 5 | JPRN-UMIN000002155 | 2009/09/01 | 06/07/2009 | Effects of falecalcitoriol on post-operative hypoparathyroidism after thyroidectomy | Effects of falecalcitoriol on post-operative hypoparathyroidism after thyroidectomy - Effects of falecalcitoriol on post-operative hypoparathyroidism after thyroidectomy | Postoperative hypoparathyroidism | In the first day after operation, we start administration of falecalcitriol at a dosage of 0.6ug once a day, when below the lower limit of serum calcium. If serum calcium level do not reach normal range, we escalete to 0.9ug/day.Oral calcium lactate is administered 3g/day in all enrolled patients.The dose is reduced when serum calcium and intact PTH level are maintained within normal range. If subjective symptoms such as tetany are worsen up, we start administration of calcium via DIV. | kawasaki medicak school | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 30 | Phase 3 | Japan |
| 6 | NCT00824226 (ClinicalTrials.gov) | January 2009 | 15/1/2009 | Magnesium Treatment in Hypoparathyroidism | Effect of Magnesium Treatment on Plasma Calcium in Hypoparathyroid Patients | Hypoparathyroidism | Dietary Supplement: magnesium | University of Tartu | NULL | Completed | 18 Years | N/A | Both | 10 | N/A | Estonia |
| 7 | JPRN-UMIN000000475 | 2006/07/01 | 01/09/2006 | Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration | Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration - The effect of sevelamer hydrochloride on relative hypoparathyroidism in hemodialysis patients | Relative hypoparathyoidism in maintenance hemodialysis patients | Replacement of calcium carbonate with sevelamer hydrochloride as phosphate binder | Hokusetsu ROD Study Group | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 40 | Not applicable | Japan |
| 8 | NCT00581828 (ClinicalTrials.gov) | January 2005 | 19/12/2007 | Does Treatment of Hypovitaminosis D Increase Calcium Absorption? | Does Treatment of Hypovitaminosis D Increase Calcium Absorption? | Osteoporosis;Osteopenia;Vitamin D Deficiency;Hypoparathyroidism;Hypercalciuria;Hypercalcemia | Drug: Vitamin D | University of Wisconsin, Madison | NULL | Completed | N/A | N/A | Female | 19 | Phase 4 | United States |
| 9 | NCT00004361 (ClinicalTrials.gov) | July 1995 | 18/10/1999 | Study of the Relationship Between Calcium Levels and Intact Parathyroid Hormone (iPTH) in Adults With Repaired or Palliated Conotruncal Cardiac Defects | Hypoparathyroidism;Tetralogy of Fallot;Pulmonary Valve Stenosis;Conotruncal Cardiac Defects;Heart Defects, Congenital;Pulmonary Atresia | Drug: calcium gluconate;Drug: sodium citrate | National Center for Research Resources (NCRR) | Ann & Robert H Lurie Children's Hospital of Chicago | Completed | 18 Years | N/A | Both | 150 | N/A | NULL | |
| 10 | NCT00001304 (ClinicalTrials.gov) | October 1991 | 3/11/1999 | Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34 | Treatment of Hypoparathyroidism With Synthetic Human Parathyroid Hormone 1-34 | Hypoparathyroidism | Drug: Synthetic Human Parathyroid Hormone 1-34;Drug: Calcitriol & Calcium | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NULL | Completed | 17 Years | 69 Years | All | 27 | Phase 2 | United States |